JPM2026 | 递交首个BLA，Summit介绍依沃西单抗后续开发计划

医药魔方Info01-14

Summit在第44届摩根大通年度医疗健康（JPM）大会上发表演讲，公布了Ivonescimab全球开发最新进展。Summit与康方生物共同推进Ivonescimab的全球开发，康方负责中国市场10项III期试验（覆盖肺、乳腺、头颈、胆道癌、胰腺癌等瘤种）及多项II期试验，Summit主导4项全球III期试验（NSCLC和结直肠癌）。到目前为止，已有4项III期试验取得积极结果，并在中国获得了2项...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603695882?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-14 14:46","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2603695882","market":"hk","top_or_hot":-1,"title":"JPM2026 | 递交首个BLA，Summit介绍依沃西单抗后续开发计划","media":"医药魔方Info","content":"<div>\n<p>Summit在第44届摩根大通年度医疗健康（JPM）大会上发表演讲，公布了Ivonescimab全球开发最新进展。Summit与康方生物共同推进Ivonescimab的全球开发，康方负责中国市场10项III期试验（覆盖肺、乳腺、头颈、胆道癌、胰腺癌等瘤种）及多项II期试验，Summit主导4项全球III期试验（NSCLC和结直肠癌）。到目前为止，已有4项III期试验取得积极结果，并在中国获得了2项...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114144910a718f3e2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPM2026 | 递交首个BLA，Summit介绍依沃西单抗后续开发计划</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPM2026 | 递交首个BLA，Summit介绍依沃西单抗后续开发计划\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-14 14:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114144910a718f3e2&s=b><strong>医药魔方Info</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summit在第44届摩根大通年度医疗健康（JPM）大会上发表演讲，公布了Ivonescimab全球开发最新进展。Summit与康方生物共同推进Ivonescimab的全球开发，康方负责中国市场10项III期试验（覆盖肺、乳腺、头颈、胆道癌、胰腺癌等瘤种）及多项II期试验，Summit主导4项全球III期试验（NSCLC和结直肠癌）。到目前为止，已有4项III期试验取得积极结果，并在中国获得了2项...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114144910a718f3e2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1720050803.USD","symbol_name":"安联全方位中国股票基金","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114144910a718f3e2&s=b","article_id":"2603695882","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114144910a718f3e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603695882","pubTimestamp":1768373210,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Summit在第44届摩根大通年度医疗健康大会上发表演讲，公布了Ivonescimab全球开发最新进展。到目前为止，已有4项III期试验取得积极结果，并在中国获得了2项批准。基于III期HARMONi研究在二线EGFR突变非小细胞肺癌中的积极结果，Summit于1月12日宣布已正式向FDA递交Ivonescimab联合化疗的生物制品许可申请。Ivonescimab有望成为一款平台型重磅炸弹药物。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1161":"生物科技","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","BK1574":"生物医药B类股","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","09926":"康方生物","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC"},"translate_title":"JPM2026 | Submit the first BLA, Summit introduces the follow-up development plan of ivosilizumab","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":0.9},"content_text":"Summit在第44届摩根大通年度医疗健康（JPM）大会上发表演讲，公布了Ivonescimab全球开发最新进展。Summit与康方生物共同推进Ivonescimab的全球开发，康方负责中国市场10项III期试验（覆盖肺、乳腺、头颈、胆道癌、胰腺癌等瘤种）及多项II期试验，Summit主导4项全球III期试验（NSCLC和结直肠癌）。到目前为止，已有4项III期试验取得积极结果，并在中国获得了2项批准。基于III期HARMONi研究在二线EGFR突变非小细胞肺癌中的积极结果，Summit于1月12日宣布已正式向FDA递交Ivonescimab联合化疗的生物制品许可申请（BLA）。目前，HARMONi-3、HARMONi-7和HARMONi-GI3三项临床试验在招募患者中。上述研究之外，Summit与Revolution Medicine合作，评估Ivonescimab联合三种新型RAS抑制剂，聚焦NSCLC、胰腺癌和结直肠癌，预计2026年第一季度启动；与GSK合作，探索Ivonescimab联合B7H3 ADC在多种实体瘤中的应用，该研究预计于2026年年中启动；此外，支持超60项研究者发起试验（IST），其中15项正在入组（含5项与MD Anderson合作），探索未覆盖的肿瘤类型及联合方案。Ivonescimab有望成为一款平台型重磅炸弹药物。此外，与IVO联合使用的新型组合疗法可能比当前的标准治疗方案更具潜力，这有望进一步扩大市场机遇。PD-1-VEGF领域全球市场规模预计超1000亿美元，其中NSCLC的免疫检查点抑制剂市场2028年预计超200亿美元。在PD-1抑制剂无效的场景（如EGFR突变NSCLC、PD-L1低表达三阴性乳腺癌）中显示潜力，单药及联合方案均可能成为重磅炸弹级产品。首席业务与战略官Dave Gancarz在问答环节表示，Ivonescimab本身存在重大机会，随着开发计划的推进，探索新型联合疗法将非常重要。例如与GSK的合作以及即将启动的与Revolution Medicine的合作，Summit将继续遵循数据，为Ivanesimab在不同肿瘤环境中寻找合适的组合，从而为患者带来最大的益处。Copyright © 2026 PHARMCUBE. All Rights Reserved.免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603695882","isCrawlerRequest":true}